Sign inJoin waitlistJoin the waitlist

RS

Rory Shallis

Hematology & Oncology · H. Lee Moffitt Cancer Center and Research Institute

Credentials: · · · · ·

History

Yale - New Haven Hospital
Until 2020
Brown University - Rhode Island Hospital
Until 2017
Brown University - Rhode Island Hospital
Until 2017
Rutgers University - Robert Wood Johnson Medical School
2014
Rutgers University - Robert Wood Johnson Medical School
2010

Research

Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges
Review · Blood Reviews · 2019 · First of 5 authors · 717 citations
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2023 · 188 citations
Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it
Review · Blood Reviews · 2019 · 157 citations

Amer Zeidan
89 papers
Jan Bewersdorf
58 papers · 47 as a resident
Nikolai Podoltsev
51 papers · 21 as a resident
Maximilian Stahl
37 papers
Talha Badar
23 papers · 2 as a fellow
Anand Patel
21 papers · 3 as a fellow
Scott Huntington
20 papers
SG
Steven Gore
19 papers
AG
Aaron Goldberg
18 papers
Yasmin Abaza
18 papers
Ehab Atallah
16 papers
JS
Jessica Stempel
16 papers · 12 as a fellow

Clinical trials

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2023–2027
Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2020–2027
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Site PI · Recruiting · Phase 1, Phase 2
Sellas Life Sciences Group
2021–2027